These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 21034677

  • 1. Development of anti-cancer drugs.
    Arrondeau J, Gan HK, Razak AR, Paoletti X, Le Tourneau C.
    Discov Med; 2010 Oct; 10(53):355-62. PubMed ID: 21034677
    [Abstract] [Full Text] [Related]

  • 2. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM.
    Oncologist; 1997 Oct; 2(1):I-II. PubMed ID: 10388032
    [Abstract] [Full Text] [Related]

  • 3. Clinical trial design in metastatic breast cancer: a commentary.
    Levine M.
    Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
    [Abstract] [Full Text] [Related]

  • 4. Anticancer Drug Development: The Way Forward.
    Connors T.
    Oncologist; 1996 Dec; 1(3):180-181. PubMed ID: 10387985
    [Abstract] [Full Text] [Related]

  • 5. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, Simpson M, Tomaszewski JE, Doroshow JH.
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [Abstract] [Full Text] [Related]

  • 6. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH.
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA, Brown PH.
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Lessons learned from independent central review.
    Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J.
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [Abstract] [Full Text] [Related]

  • 16. Approaches to the development and marketing approval of drugs that prevent cancer.
    Kelloff GJ, Johnson JR, Crowell JA, Boone CW, DeGeorge JJ, Steele VE, Mehta MU, Temeck JW, Schmidt WJ, Burke G.
    Cancer Epidemiol Biomarkers Prev; 1995 Jan; 4(1):1-10. PubMed ID: 7894318
    [Abstract] [Full Text] [Related]

  • 17. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.
    Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C.
    J Clin Oncol; 2008 Apr 20; 26(12):2000-5. PubMed ID: 18421052
    [Abstract] [Full Text] [Related]

  • 18. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G, Cancer Vaccine Clinical Trial Working Group.
    J Immunother; 2007 Jan 20; 30(1):1-15. PubMed ID: 17198079
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The Goal of Cancer Treatment.
    Balis FM.
    Oncologist; 1998 Jan 20; 3(4):V. PubMed ID: 10388118
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.